Skip to Main Content

Paper Details

miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA.
Cancer Lett
25
2020
9-cis-retinoic acid, MicroRNA, RXRA, Retinoid, Retinoid X receptor alpha, miR, miR-191, normal tissue, patient, patients, primary cell line, prostate cancer, prostate cancer cells, radiorecurrent prostate cancer, retinoids, tumor
Alitretinoin, Animals, Antineoplastic Agents, Biomarkers, Tumor, Cell Line, Tumor, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Down-Regulation, Gene Expression Regulation, Neoplastic, Gene Knockdown Techniques, Humans, Kallikreins, Kaplan-Meier Estimate, Male, Mice, MicroRNAs, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Primary Cell Culture, Prognosis, Prostate, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Radiation Tolerance, Retinoid X Receptor alpha, Survival Rate, Time Factors, Xenograft Model Antitumor Assays
Author NameAffiliation
Jessica RaySunnybrook Research Institute, University of Toronto
Charles HaugheyQueen's University Belfast
Christianne HoeySunnybrook Research Institute, University of Toronto
Jouhyun JeonOntario Institute for Cancer Research
Ross MurphyQueen's University Belfast
Lara Dura-PerezQueen's University Belfast
Nuala McCabeQueen's University Belfast
Michelle R DownesUniversity of Toronto
Suneil JainQueen's University Belfast
Paul C BoutrosUniversity of Toronto, Canada Ontario Institute for Cancer Research
Ian G MillsQueen's University Belfast, University of Oxford
Stanley K LiuSunnybrook Research Institute, University of Toronto
  • 1 - 12

Datasets

Release 1.2